Media

Chiesi completes European regulatory submissions for the transition of Fostair® (beclometasone / formoterol) and Trimbow® (beclometasone / formoterol / glycopyrronium) to a next-generation, carbon minimal, propellant

PROCYSBI® [mercaptamine bitartrate (cysteamine) gastro-resistant hard capsules] recommended for routine commissioning by NHS England for eligible patients with nephropathic cystinosis